Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women - 28/08/11
, Othon Lalos, MD b, Robert M Freeman, MD c, Philip van Kerrebroeck, MD dThe Nocturia Study Group
Reprint requests: Gunnar Lose, MD, Department of Gynaecology, Glostrup Hospital, Nordre Ringvej, DK-2600 Glostrup, DenmarkGlostrup, Denmark, Umea, Sweden, Plymouth, United Kingdom, and Maastricht, The Netherlands
Abstract |
Objective |
The purpose of this study was to investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in women.
Study design |
Women aged 18 years or older with nocturia (≥2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period. After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks.
Results |
In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72). For desmopressin, 33 (46%) patients had a 50% or greater reduction in nocturnal voids against baseline levels compared with 5 (7%) patients receiving placebo (P<.0001). The mean number of nocturnal voids, duration of sleep until the first nocturnal void, nocturnal diuresis, and ratios of nocturnal per 24 hours and nocturnal per daytime urine volumes changed significantly in favor of desmopressin versus placebo (P<.0001). In the dose-titration phase headache (22%), nausea (8%), and hyponatremia (6%) were reported. Two deaths occurred, although neither could be directly associated with the study drug.
Conclusion |
Oral desmopressin is an effective and well-tolerated treatment for nocturia in women.
Le texte complet de cet article est disponible en PDF.Keywords : Arginine vasopressin, desmopressin, nocturia, nocturnal polyuria
Plan
 | Supported by a grant from Ferring Pharmaceuticals. |
Vol 189 - N° 4
P. 1106-1113 - octobre 2003 Retour au numéro
Article précédent
- Urethral pressure changes in response to squeeze: a population-based study in healthy and incontinent 53- to 63-year-old women
- Pia M Teleman, Marianne Gunnarsson, Jonas Lidfeldt, Christina Nerbrand, Göran Samsioe, Anders Mattiasson
- Pelvic floor nerve conduction studies: establishing clinically relevant normative data
- Ambre L Olsen, Mark Ross, R.Brent Stansfield, Clarence Kreiter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?